Clinical features of head and neck cancer patients with brain metastases: A retrospective study of 88 cases.

Abstract

Brain metastases (BM) arising from head and neck cancer (HNC) are rare and not well characterized. This study aims to describe the clinicopathological features, treatments, prognostic factors, and survival in HNC patients with BM. Non-thyroid HNC patients referred to BC Cancer from 1998 to 2016 were retrospectively reviewed for BM. The Kaplan-Meier method, log-rank test, and Cox regression analysis were used to assess post-BM survival and prognostic factors. Out of 9432 HNC patients, 88 patients developed BM (0.9%, median follow-up 3.4years). On average, the BM were diagnosed 18.5months after the primary diagnosis and tended to arise after distant metastases to extracranial sites (85%) such as the lungs (78%). At BM presentation, 84% were symptomatic and two thirds had a poor performance status (ECOG≥2, 68%). The median post-BM survival was 2.5months (95% CI 2.1-3.3months). On multivariable analysis, management of BM with radiotherapy (RT) alone (3.3months, 95% CI 2.3-4.6, p=0.005) and RT with surgery (4.4months, 95% CI 2.8-6.9, p<0.001) was associated with longer survival compared to best supportive care alone (1.4months, 95% CI 1.0-2.0months). Age, sex, performance status, sub-localization of the primary HNC, presence of extracranial metastases, and number of intracranial metastases were not associated with post-BM survival (all p≥0.05). This is the largest study to date in BM from HNC. BM occur late in the course of HNC and carry a poor prognosis. Treatment with intracranial radiotherapy both with and without surgery was associated with improved survival.